Session » Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2402

Acoustic Emissions Generated By the Temporomandibular Joint of Patients with Juvenile Idiopathic Arthritis and Their Implication on Patient Assessment and Screening: A Pilot Study

9:00AM-11:00AM: Abstract Number: 2394

Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching

9:00AM-11:00AM: Abstract Number: 2392

Are Single Nucleotide Polymorphisms in Methotrexate Transporter Proteins Associated with Methotrexate Intolerance in Juvenile Idiopathic Arthritis?

9:00AM-11:00AM: Abstract Number: 2388

Assessment of Treatment Responses, with Special Reference to Remission Using Juvenile Arthritis Disease Activity Score (JADAS), in the Different Categories of Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2384

Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany

9:00AM-11:00AM: Abstract Number: 2399

Bone Density, Structure and Strength in Canadian Children and Youth with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

9:00AM-11:00AM: Abstract Number: 2398

Children with Enthesitis Have Worse Quality of Life, Function, and Pain, Irrespective of Their Juvenile Arthritis Category

9:00AM-11:00AM: Abstract Number: 2406

Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents

9:00AM-11:00AM: Abstract Number: 2408

Comparison of the Tear Cytokine and Chemokine Profile of Children with JIA and JIA-Associated Uveitis

9:00AM-11:00AM: Abstract Number: 2389

Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)

9:00AM-11:00AM: Abstract Number: 2405

Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis

9:00AM-11:00AM: Abstract Number: 2390

Incidence of and Risk Factors for Adrenal Suppression Following Ultrasound-Guided Intra-Articular Corticosteroid Injection with Triamcinolone Acetonide in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2393

Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?

9:00AM-11:00AM: Abstract Number: 2381

Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years

9:00AM-11:00AM: Abstract Number: 2379

Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2391

Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients

9:00AM-11:00AM: Abstract Number: 2407

New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2383

Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry

9:00AM-11:00AM: Abstract Number: 2404

Quality of Life Assessment in Juvenile Idiopathic Arthritis: A Single Center Assessment

9:00AM-11:00AM: Abstract Number: 2382

Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan

9:00AM-11:00AM: Abstract Number: 2396

Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients

9:00AM-11:00AM: Abstract Number: 2387

Resurrecting Triamcinolone Hexacetonide (the Steroid Formerly Known as Aristospan®): Efficacy and Safety of a Compounded Preparation of Triamcinolone Hexacetonide for Intra-Articular Injection in Children with Arthritis

9:00AM-11:00AM: Abstract Number: 2386

Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment

9:00AM-11:00AM: Abstract Number: 2378

Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category

9:00AM-11:00AM: Abstract Number: 2385

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices

9:00AM-11:00AM: Abstract Number: 2401

The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study

9:00AM-11:00AM: Abstract Number: 2397

The Impact of Adalimumab on Growth in Patients with Pediatric Enthesitis-Related Arthritis

9:00AM-11:00AM: Abstract Number: 2380

The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry

9:00AM-11:00AM: Abstract Number: 2403

The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study

9:00AM-11:00AM: Abstract Number: 2395

Tumor Necrosis Factor-α Inhibitor (TNFi)-Induced Psoriasis: Prevalence and Response to Therapy in Patients with Juvenile Idiopathic Arthritis (JIA) in Two Children’s Hospitals

9:00AM-11:00AM: Abstract Number: 2400

Validating and Developing a Selected Questionnaire to Predict Early Diagnosis of Juvenile Idiopathic Arthritis in German Population

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].